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Summary
 
Osteoclasts are terminally differentiated cells derived from hematopoietic stem cells. However,
how their precursor cells diverge from macrophagic lineages is not known. We have identified
early and late stages of osteoclastogenesis, in which precursor cells sequentially express c-Fms
followed by receptor activator of nuclear factor 
 
k
 
B (RANK), and have demonstrated that RANK
 
expression in early-stage of precursor cells (c-Fms
 
1
 
RANK
 
2
 
) was stimulated by macrophage
colony-stimulating factor (M-CSF). Although M-CSF and RANKL (ligand) induced commit-
 
ment of late-stage precursor cells (c-Fms
 
1
 
RANK
 
1
 
) into osteoclasts, even late-stage precursors
have the potential to differentiate into macrophages without RANKL. Pretreatment of precursors
with M-CSF and delayed addition of RANKL showed that timing of RANK expression and
subsequent binding of RANKL are critical for osteoclastogenesis. Thus, the RANK–RANKL
system determines the osteoclast differentiation of bipotential precursors in the default pathway of
macrophagic differentiation.
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B
 
one is continuously forming and being resorbed. This
process is accomplished by precise coordination of two
cell types: osteoblasts, which deposit the calcified bone ma-
trix, and osteoclasts, which are derived from hematopoietic
stem cells (1–5) and resorb the bone tissue. Osteoclasts are
 
large multinucleated cells (MNCs)
 
1
 
 located on endosteal bone
surfaces and the periosteal surface beneath the periosteum.
Mononuclear osteoclasts differentiate from the same pre-
cursor cells as macrophages (6–8) and fuse to form multinu-
clear osteoclasts. However, how osteoclasts differentiate from
precursors and their relationship to macrophage precursors
is still controversial. It has been shown that mice lacking
c-Fos are osteopetrotic due to a differentiation block in
bone-resorbing osteoclasts, even though macrophage differ-
entiation is intact and osteoclast differentiation can be res-
cued by introduction of Fos protein (9, 10).
Osteoclasts characteristically show a high level of cell ad-
hesion, and their growth and differentiation are anchorage
dependent. In this aspect, assays of osteoclast precursor cells
require coculture with stromal cells rather than colony for-
mation in semisolid cultures. Osteoclastogenesis in culture
depends on interaction with stromal cells, which provides
the microenvironment essential for this process (11, 12).
One of the critical factors produced by stromal cells is M-CSF
(13–16). A lack of osteoclasts is observed in osteopetrotic
 
op/op
 
 mutant mice, which lack functional M-CSF (17–19).
It is thought that the M-CSF receptor, c-Fms tyrosine ki-
nase, might be expressed on osteoclast precursor cells. Hof-
stetter et al. (20) reported that c-Fms mRNA was detected
in cells at late stages of osteoclastogenesis and in mature os-
teoclasts. Another factor important for osteoclastogenesis is
osteoprotegerin ligand (OPGL)/osteoclast differentiation
factor (ODF), which was cloned from an osteoblastic cell
line (21, 22). A new member of the TNFL family, desig-
nated TNF-related activation-induced cytokine (TRANCE)
or receptor activator of nuclear factor (NF)-
 
k
 
B (RANK)L
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 BM, bone marrow; Dex, dexamethasone;
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factor; OPG, osteoprotegerin; RANK, receptor activator of nuclear factor
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B; RT, reverse transcriptase; s, soluble; SCF, stem cell factor; TRAFs,
TNFR-associated factors; TRAP, tartrate-resistant acid phosphatase.  
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was cloned independently. Its predicted amino acid se-
quence is identical to that of OPGL/ODF. TRANCE was
identified as an activator of c-Jun NH
 
2
 
-terminal kinase (JNK)
in T cells (23), and RANKL was shown to be a ligand for
RANK, a new member of the TNFR family derived from
dendritic cells (24). In vitro results suggest that signaling
mediated by TNFR-associated factors (TRAFs) is impor-
tant for the activation of the stress kinase pathway (SAPK/
JNK) and the transcription factor NF-
 
k
 
B (25–27). In addi-
tion, the RANK intracellular domain contains two distinct
TRAF binding domains (26, 28), and TRAF6 deficiency
results in osteopetrosis (29). Mice in which both the p50 and
p52 subunits of NF-
 
k
 
B are disrupted fail to generate ma-
ture osteoclasts and B cells (30, 31). Moreover, RANKL-
deficient mice show severe osteopetrosis and a defect in
tooth eruption (32).
Here, to clarify the commitment and differentiation
pathway of osteoclasts, we have identified the early and late
stages of osteoclast precursor cells using anti–c-Kit, Mac-1,
c-Fms, and RANK mAbs. We have observed sequential
expression of c-Fms and RANK and analyzed the function
of each factor in osteoclastogenesis.
 
Materials and Methods
 
Mice.
 
8–10-wk-old female C57BL/6 mice were purchased from
Japan SLC. Bone marrow (BM) cells were freshly prepared from
femur and tibia and used as a source of hematopoietic precursors.
 
Reagents.
 
1,25-dihydroxyvitamin D
 
3
 
 (1,25-[OH]
 
2
 
D
 
3
 
) was
provided by Dr. Ishizuka (Teijin Institute for Biomedical Re-
search, Tokyo, Japan). Recombinant M-CSF and anti–mouse
M-CSF neutralizing antibody were purchased from R & D Sys-
tems, Inc. Recombinant IL-7 and recombinant IL-3 were pro-
vided by Toray Industries Inc. Recombinant stem cell factor
(SCF) was a gift from Chemo-Sero-Therapeutic Co., Ltd. Eryth-
ropoietin (Epo) was a gift from Snow-Brand Milk Product Co. 
 
Preparation of Mouse BM Mononuclear Cells.
 
Mice were killed
by cervical dislocation, and the tibiae and femora were removed
and dissected free from adhering soft tissues. The bone ends were
cut off with a scalpel, and the marrow was flushed with 
 
a
 
-modi-
fied (
 
a
 
-)MEM (GIBCO BRL) containing 10% FCS (JRH Bio-
sciences). Mononuclear cells were isolated by centrifugation of
total BM cells on Lymphep™ (Nycomed Pharmaceuticals) ac-
cording to the manufacturer’s instructions.
 
Preparation of Soluble RANKL.
 
A DNA fragment encoding the
extracellular domain (Asp
 
76
 
–Asp
 
316
 
) of RANKL was prepared using
reverse transcriptase (RT)-PCR from total RNA of ST2 stromal
cells that were cultured in the presence of 1,25-(OH)
 
2
 
D
 
3
 
 (10
 
2
 
8
 
 M)
for 4 d. PCR primers were as follows: 5
 
9
 
-CCGCTCGAGCGTC-
TATGTCCTGAACTTTGA-3
 
9
 
 (sense) and 5
 
9
 
-CCCAAGCTTG-
ATCCTAACAGAATATCAGAAGACA-3
 
9
 
 (antisense).
The PCR product was digested with HindIII and XhoI and li-
gated into the HindIII and XhoI sites of the pSecTag2 vector (In-
vitrogen Corp.) to yield pSecTag2–soluble (s)RANKL containing
His
 
6
 
 and myc tags. pSecTag2–sRANKL was transfected into
COS7 cells cultured in DMEM (Life Technologies, Inc.) con-
taining 10% FCS, and the supernatant was collected every 4 d for
12 d. sRANKL was purified from the supernatant using TALON
and TALON Superflow Metal Affinity Resin (Clontech). The
supernatant was applied to a chromatography column (Bio-Rad
 
Labs.) filled with affinity resin, and the trapped proteins were eluted
in 125 nM imidazol and fractionated. The high concentration frac-
tion was collected and applied to a PD-10 column (Amersham
Pharmacia Biotech, Inc.), eluted in PBS to eliminate the imidazol,
and fractionated. Fractions containing a large amount of sRANKL
were concentrated by a centricon concentrator (Amicon, Inc.).
 
Cell Lines.
 
Mouse BM–derived stromal cell line ST2 (a gift
from Dr. Hayashi, Tottori University, Yonago, Japan) was main-
tained in RPMI 1640 (GIBCO BRL) supplemented with 10%
FCS with 10
 
2
 
5
 
 M of 2-ME (GIBCO BRL) at 37
 
8
 
C in humidified
5% CO
 
2
 
 air. Cells were harvested every 3 d using 0.05% trypsin–
EDTA (GIBCO BRL), and 10
 
5
 
 cells were passaged on 100-mm
culture dishes (Falcon 3003; Becton Dickinson Labware).
The newborn calvaria-derived mouse stromal cell line OP9 (a
gift from Dr. Kodama, Bayer Yakuhin Ltd., Kyoto, Japan) was
maintained in 
 
a
 
-MEM supplemented with 20% FCS at 37
 
8
 
C in
humidified 5% CO
 
2
 
 air. Cells were harvested every 3 d using
0.05% trypsin–EDTA, and 1.5 
 
3
 
 10
 
5
 
 cells were resuspended on
100-mm cell culture dishes.
 
Immunofluorescence Staining and Cell Sorting.
 
The cell staining
procedure for flow cytometry was performed as previously de-
scribed (33). The mAbs used in immunofluorescence staining were
anti–c-Kit antibody (ACK2; a gift from Dr. S.-I. Nishikawa, Ky-
oto University, Kyoto, Japan), anti–Mac-1 (CD-11b) antibody
(M1/70; PharMingen), anti–c-Fms antibody (AFS98; a gift from
Toray Industries Inc., anti-RANK antibody (muRANK-M395; a
gift from Immunex Corp.), anti-CD51 antibody (H9.2B8; Phar-
Mingen), and anti-B220 antibody (RA3-6B2; PharMingen). The
mAbs used were either biotinylated or fluoresceinated. Biotiny-
lated mAbs were detected with streptavidin-conjugated allophy-
cocyanin (Caltag Labs.) or streptavidin-conjugated Red613 (GIBCO
BRL). The following rat Igs were used as isotype controls: biotin-
ylated IgG2a and IgG2b and fluoresceinated IgG2a and IgG2b
(PharMingen). Cells were incubated for 15 min on ice with
CD16/32 (Fc
 
g
 
III/II receptor; 1:100; FcBlock™; PharMingen)
before staining with the first antibody. 10
 
6
 
 cells/100 
 
m
 
l were sus-
pended in 5% FCS/PBS (washing buffer). Cells were stained with
the first antibody, incubated for 30 min on ice, and washed twice
with washing buffer. The secondary antibody was added, and the
cells were incubated for 30 min on ice. After incubation, cells were
washed twice with washing buffer and suspended in washing
buffer for FACS
 
®
 
 analysis. The stained cells were analyzed and
sorted by FACSVantage™ (Becton Dickinson).
 
Cytochemical Staining.
 
Sorted cells were centrifuged onto mi-
croscope slides using a cytospin centrifuge (Shandon Southern
Products) and stained with May-Grünwald-Giemsa staining solu-
tion (Merck KGaA).
 
Osteoclast Formation Assay.
 
5 
 
3
 
 10
 
3
 
 ST2 cells were plated in
96-well plates (PRIMARIA; Becton Dickinson Labware) 1 d be-
fore coculture with sorted BM cells. Cultures were maintained in
 
a
 
-MEM/10% FCS with 10
 
2
 
8
 
 M 1,25-(OH)
 
2
 
D
 
3
 
 and 10
 
2
 
7
 
 M
dexamethasone (Dex). Tartrate-resistant acid phosphatase (TRAP)
staining was performed on day 4, and the TRAP solution assay
(TRAP activity) was performed on day 7 or 10. Cocultures were
scaled down to 100, 50, 40, 30, 20, 10, 8, 6, 5, 4, 2, and 1 cell in
100 
 
m
 
l for a limiting dilution assay.
To assay osteoclast formation without a stromal layer, sorted
BM cells were cultured in 
 
a
 
-MEM/10% FCS in the presence of
recombinant M-CSF (100 ng/ml) and sRANKL (25 ng/ml).
 
TRAP Staining.
 
After aspiration of medium, cells were fixed
with 1% glutaraldehyde (Wako Pure Chemical Industries, Ltd.)
in PBS for 15 min at room temperature. Cells were stained for
TRAP using a histochemical kit (no. 387; Sigma Chemical Co.) 
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according to the manufacturer’s instructions. TRAP
 
1
 
 cells were
scored as osteoclasts microscopically.
 
TRAP Solution Assay (TRAP Activity).
 
In the TRAP solu-
tion assay, enzyme activity was examined by the conversion of
 
a
 
-naphthyl phosphate (4 mmol/liter; Sigma Chemical Co.) to
 
a
 
-naphthol in the presence of 2 mol/liter 
 
l
 
-tartrate solution
(Sigma Chemical Co.) in each well. Absorbance was measured at
405 nm using a microplate reader (model 550; Bio-Rad Labs.).
 
Analysis of Differentiation in Cultured Cells.
 
c-Kit
 
1
 
Mac-1
 
dull
 
c-Fms
 
2
 
cells were cultured for 2 d in 
 
a
 
-MEM/10% FCS in the presence
of SCF (100 U/ml), and c-Fms expression was examined. Sorted
c-Kit
 
1
 
Mac-1
 
dull
 
c-Fms
 
1
 
 cells derived from BM were cultured for
3 d in 
 
a
 
-MEM/10% FCS plus either M-CSF (30 ng/ml) or IL-3
(100 U/ml), and the expression of RANK was analyzed. To inves-
tigate whether c-Kit
 
1
 
Mac-1
 
dull
 
c-Fms
 
2
 
 cells and c-Kit
 
1
 
Mac-1
 
dull
 
c-Fms
 
1
 
 cells differentiate into B cells, these cells were cocultured
with OP9 stromal cells for 10 d in RPMI 1640/10% FCS in the
presence of IL-7 (20 U/ml). After 10 d in culture, the expression
of B220 was analyzed using FACSVantage™.
 
RT-PCR Analysis.
 
An RNeasy mini Kit (QIAGEN GmbH)
was used for isolation of total RNA from total BM cells or frac-
tionated BM cells. Total RNA was reverse transcribed using an
RT for PCR kit (Clontech). The cDNAs were amplified using
an Advantage polymerase mix (Clontech) in a GeneAmp PCR
system (model 9700; Perkin-Elmer Corp.) for 25–30 cycles. Se-
quences of gene-specific primers for RT-PCR were as follows:
5
 
9
 
-mRANK, CCAGGGGACAACGGAATCAG; 3
 
9
 
-mRANK,
 
GGCCGGTCCGTGTACTCATC; 5
 
9
 
-m
 
b
 
-actin, TCGTGCGT-
GACATCAAAGAG; and 3
 
9
 
-m
 
b
 
-actin, TGGACAGTGAGGC-
CAGGATG. Each cycle consisted of 30 s denaturation at 94
 
8
 
C
and 4 min annealing/extension at 70
 
8
 
C.
 
In Vitro Colony Assay.
 
To compare CFU-C (culture) ac-
tivity between c-Kit
 
1
 
Mac-1
 
dull
 
c-Fms
 
6
 
 cells, 10
 
3
 
 cells were cul-
tured in 1 ml of culture medium containing 
 
a
 
-MEM, 1.2% meth-
ylcellulose (1,500 centipoise; Aldrich Chemical Co.), 30% FCS,
1% deionized BSA, 50 mM 2-ME, 100 U/ml IL-3, 2 U/ml Epo,
and 100 ng/ml SCF. After 7 d in culture, aggregates of 50 or more
cells were counted as a single colony.
For in vitro osteoclast colony formation assay, 10
 
3
 
 R3 cells were
plated in methylcellulose medium. In brief, cells were embedded in
1 ml of 1.2% methylcellulose, 30% FCS, 1% deionized BSA, 50
mmol/liter 2-ME, and 100 ng/ml M-CSF in the presence or ab-
sence of sRANKL (25 ng/ml) in 
 
a
 
-MEM. The culture dishes
were incubated in humidified atmosphere at 37
 
8
 
C with 5% CO
 
2
 
.
After 7 d, the colonies were counted, picked up, and stained for
nonspecific esterase, May-Grünwald-Giemsa, and TRAP.
Results
Isolation of Osteoclast Precursor Cells from Mouse BM Mono-
nuclear Cells. To characterize and isolate osteoclast precursor
cells, expression of cell surface markers was analyzed (Fig.
1 A). Of the c-Kit1 BM mononuclear cells, 37.5% were
Figure 1. Differentiation of TRAP1 cells from fractionated mouse BM
mononuclear cells. (A) Expression of c-Fms and Mac-1 (CD11b) on BM
mononuclear cells was analyzed by FACS® gated with c-Kit1 cells. c-Kit1 cells
were subdivided further into four fractions based on expression of c-Fms and
Mac-1. R3, c-Kit1Mac-1dullc-Fms1; R4, c-Kit1Mac-1highc-Fms1; R5, c-Kit1
Mac-1dullc-Fms2; and R6, c-Kit1Mac-1highc-Fms2. (B) Fractionated cells were examined by May-Grünwald-Giemsa staining. (a) R3; (b) R4; (c) R5;
and (d) R6. Scale bar, 50 mm. (C) 103 cells of each fraction were cocultured with ST2 stromal cells in the presence of 1,25-(OH)2D3 (1028 M) and Dex
(1027 M), and the number of TRAP1 cells was determined on day 4. (D) Relative TRAP activities were measured on days 7 and 10 of coculture with
ST2 stromal cells. TRAP activity from unfractionated BM cells was set at 1.0.1744 Commitment and Differentiation of Osteoclasts
c-Fms1 and 56.1% were Mac-11. Using contour blot anal-
yses, four populations of c-Kit1 cells were detected: Mac-1dull
c-Fms1 (R3), Mac-1highc-Fms1 (R4), Mac-1dull c-Fms2 (R5),
and Mac-1highc-Fms2 (R6). These cells were fractionated, and
further analyses were performed. The percentages of these
populations in both BM mononuclear cells and c-Kit1 cells
is shown in Table I. The morphology of cells of each frac-
tion was examined by May-Grünwald Giemsa staining (Fig.
1 B). R3 and R5 cells were immature cells showing a large
N/C ratio, whereas most of the R4 and R6 cells were ma-
ture cells, including macrophages or neutrophils.
TRAP is an enzyme highly expressed in both immature
and mature osteoclasts. To determine which fractionated
cells differentiate into TRAP1 cells, 103 cells of each frac-
tion were cocultured with an ST2 stromal cell line in the
presence of 1,25-(OH)2D3 and Dex (Fig. 1, C and D). To
detect TRAP1 mononuclear or multinuclear osteoclasts,
TRAP staining was performed on day 4 (Fig. 1 C) and
TRAP activity (TRAP solution assay) was measured on
days 7 and 10 (Fig. 1 D). The number of TRAP1 cells in
the R3 fraction was 10-fold higher than observed in un-
fractionated cells (Fig. 1 C). Relative TRAP activity (TRAP
activity in each cell fraction/TRAP activity in unfraction-
ated BM mononuclear cells) was highest in fraction R3 on
day 7. In contrast, on day 10, the highest TRAP activity
was detected in fraction R5 (1.55 6 0.20) compared with
R3 (1.17 6 0.01). The R4 and R6 fractions showed low
TRAP activities on both days 7 and 10.
These data suggest that the R3 fraction contains a higher
proportion of osteoclast precursor cells than do other pop-
ulations (R4, R5, and R6) and that R5 cells also contain
osteoclast precursor cells that are less mature than R3 cells.
Induction of c-Fms Expression during Osteoclast Differentiation.
To investigate whether R5 cells (c-Kit1Mac-1dullc-Fms2)
differentiate to R3 cells (c-Kit1Mac-1dullc-Fms1), the ex-
pression of c-Fms was analyzed after cultivation (Fig. 2 A).
c-Fms2 cells in R5 or R6 were sorted and cultured in SCF
(100 ng/ml), as they expressed c-Kit receptors. After 2 d
in culture, 42.2% of cultured R5 cells (R59) expressed c-Fms
and 7.1% of c-Fms1 cells were also c-Kit1. In contrast, of
cultured R6 cells (R69), 9.3% were c-Fms1 cells and 0.4%
were c-Kit1c-Fms1 cells. Moreover, of R59 cells, c-Kit1
c-Fms1 cells were mainly Mac-1dull (80.3%; Fig. 2 B). To de-
termine if c-Fms1 cells in R59 or R69 could undergo osteo-
clastic differentiation, both cell fractions were cocultured
with ST2 stromal cells for 4 d in the presence of both 1,25-
Table I. Proportion of Osteoclast Precursor Cells
Fraction BM mononuclear cells Gated with c-Kit1 cells
%%
R3 0.53 6 0.04 13.4 6 0.6
R4 0.20 6 0.09 4.8 6 1.9
R5 1.99 6 0.08 50.0 6 3.7
R6 0.72 6 0.13 18.6 6 1.3
BM mononuclear cells were stained with anti–c-Kit, anti–Mac-1, and
anti–c-Fms antibodies and were gated with c-Kit1 cells. c-Kit1 cells
were subdivided into four fractions on the basis of expression of Mac-1
and c-Fms. R3, c-Kit1Mac-1dullc-Fms1; R4, c-Kit1Mac-1highc-Fms1;
R5, c-Kit1Mac-1dullc-Fms2; and R6, c-Kit1Mac-1highc-Fms2. Numbers
represent the mean percentage 6 SD.
Figure 2. Differentiation of c-Kit1Mac-
1dullc-Fms2 cells. Cells derived from R5
and R6 fractions were cultured for 2 d with
SCF (100 ng/ml; cultured cells were desig-
nated R59 and R69, respectively). (A) Ex-
pression of c-Fms on R59 and R69 cells. A
gate was set on c-Fms1 cells, and the ex-
pression of c-Kit was analyzed. A fluores-
cence histogram shows the c-Kit staining
profile of the fraction gated with c-Fms1.
(B) Expression of Mac-1 and c-Fms on c-Kit1 cells. (C) c-Fms1 cells were sorted from R59 or R69. 103 or 2.5 3 102 cells of each fraction were cocul-
tured with ST2 stromal cells and 1,25-(OH)2D3 (1028 M) for 4 d, and TRAP activity was measured. (D) Limiting dilution analysis of unfractionated BM
mononuclear cells (n), R3 (d), R5 (j), and c-Kit1c-Fms1 R59 cells (u). Cells were cocultured with ST2 stromal cells for 4 d, and the percentages of
TRAP1 cells were determined.1745 Arai et al.
(OH)2D3 and Dex and assayed for TRAP activity (Fig. 2 C).
Although c-Fms1 cells of R59 differentiated to osteoclasts,
c-Fms1 cells of R69 did not differentiate into TRAP1 cells.
R69 cells were mature granulocytes and macrophages.
To analyze the proportion of osteoclast precursor cells in
unfractionated BM cells, R3, R5, or c-Kit1c-Fms1 R59
cells, each fraction was cultured for 4 d on ST2 stromal cells
and scored for TRAP1 cells by limiting dilution analysis
(Fig. 2 D). Limiting dilution of BM cells, R3, R5, and c-Kit1
c-Fms1 R59 cells revealed 2.0% (1/49.3; unfractionated
BM), 20.4% (1/4.9; R3), 3.4% (1/29.8; R5), or 16.4% (1/
6.1; c-Kit1c-Fms1 R59) TRAP1 cells. R3 or c-Kit1c-Fms1
R59 cells contained 10-fold more osteoclast precursor cells
than did unfractionated BM cells. These data suggest that
c-Fms2 cells differentiate to osteoclasts through the induc-
tion of c-Fms.
Differentiation Capacity of Osteoclast Precursor Cells. c-Fms
expression increased during cultivation. As c-Kit1c-Fms1
R59 cells contained the same proportion of osteoclast pre-
cursor cells as did R3 cells, we speculated that R5 cells are
less mature than R3 cells. To examine the capacity of those
osteoclast precursor cells to differentiate to other lineages, a
colony assay using R3 or R5 cells was performed (Table
II). 103 cells from each fraction were cultured with methyl-
cellulose semisolid medium in the presence of SCF (100 ng/
ml), IL-3 (100 U/ml), and Epo (2 U/ml) for 7 d. The num-
bers of colonies (CFU-GEMM [granulocyte, erythrocyte,
macrophage, megakaryocyte] burst forming unit-erythrocyte,
CFU-GM [granulocyte, macrophage], CFU-G, and CFU-M
[macrophage]) were counted under an inverted microscope.
Most colonies derived from R3 cells were macrophage colo-
nies. In contrast, R5 cells contained more CFU-GM than
CFU-M. Moreover, CFU-GEMM or burst forming unit-
erythrocyte–derived colonies were observed in R5 cells.
To analyze the ability of R3 or R5 to differentiate into a
B cell lineage, 104 cells of each fraction were cocultured
with the OP9 stromal cell line and IL-7 (20 U/ml; Table
III). After 10 d in culture, the number of expanded nonad-
herent cells was 73-fold more in R5 (7.9 6 0.6 3 106 cells)
than in R3 (1.0 6 0.2 3 105 cells), and 47.0% of R3 or
93.9% of R5 cells were B2201 cells. These data suggest that
R5 cells are more immature than R3 cells and that R5 cells
can differentiate not only into osteoclast but also into my-
eloid, erythroid, or B cell lineages.
Induction of RANK Expression with M-CSF in Osteoclast
Precursor Cells. Expression of RANK in fractionated cells
was examined by RT-PCR and FACS®. To examine
whether M-CSF induces RANK mRNA expression, un-
fractionated BM mononuclear cells were cultured for 72 h
in the presence of IL-3 (100 U/ml) or M-CSF (30 ng/ml).
Both IL-3 and M-CSF are able to support the differentia-
tion of macrophagic differentiation. The expression of RANK
mRNA was detected in a 24-h incubation with M-CSF
and a 72-h incubation with IL-3 (Fig. 3 A). Subsequently,
fractionated cells were cultured with M-CSF for 48 h. Be-
fore induction with M-CSF, very low levels of RANK
mRNA were detected in all fractionated cells except R6
cells (Fig. 3 B). After incubation for 48 h, the expression of
RANK mRNA was obvious in the R3 fraction. FACS®
analyses demonstrated that 5.4% of unfractionated BM cells
were RANK1 (data not shown). Of R3 cells, 15.7% were
RANK1, and 1.5% of R5 cells were RANK1 (Fig. 3 C).
The expression of RANK protein in R3 or R5 cells was
analyzed by FACS® after incubation with M-CSF for 24 or
72 h (Fig. 3 C). The percentage of RANK1 cells in R3 in-
creased with longer incubations with M-CSF (41.3% for a
24-h incubation and 58.4% for a 72-h period). Although a
similar increase was also observed in R5 cells, the overall
percentage of RANK1 R5 cells was lower than that of R3
cells (2.6% after a 24-h incubation and 11.5% after 72 h). To
characterize RANK1 or RANK2 cells in the R3 fraction
cultured with M-CSF, cells were sorted with a RANK mAb,
and the expression of c-Kit, Mac-1, and c-Fms was analyzed.
After 24 h in culture with M-CSF, sorted RANK1 cells
Table II. Colony Assay on Osteoclast Precursor Cells
Fraction
No. colonies per 103 cells
CFU-GEMM BFU-E CFU-GM CFU-G CFU-M
R3 0 6 00  6 0 3.7 6 0.6 1.7 6 0.6 20.3 6 3.8
R5 2.0 6 1.0 2.3 6 1.2 39.0 6 6.6 14.7 6 3.1 23.0 6 4.4
103 cells of each fraction were cultured in methylcellulose medium containing IL-3, SCF, and Epo. After 7 d in culture, a colony containing .50
cells was scored as a single colony. The data shown represent the mean colony number 6 SD of triplicate samples. BFU-E, burst forming unit-
erythrocyte.
Table III. Differentiation of B Cells
Fraction No. nonadherent cells
B2201 cells
(total no. B2201 cells)
%
R3 1.0 6 0.2 3 105 47.0 (5.0 6 1.0 3 104)
R5 7.9 6 0.6 3 106 93.9 (7.4 6 0.5 3 106)
104 cells of each fraction were cocultured with OP9 stromal cells with IL-7
(20 ng/ml) for 10 d. After cultivation, nonadherent cells were collected
and analyzed for the expression of B220. Numbers represent mean 6 SD.1746 Commitment and Differentiation of Osteoclasts
To examine whether M-CSF induces the expression of
RANK on RANK2 R3 cells, R3 cells were subdivided
into RANK1 and RANK2 fractions. RANK2 R3 cells were
cultured in the presence of M-CSF with or without anti–
mouse M-CSF neutralizing antibody, and the expression of
RANK was analyzed by RT-PCR. The expression of
RANK was detected in freshly isolated RANK1 R3 cells
and cultured RANK2 R3 cells. However, RANK expres-
sion was significantly reduced by the addition of mouse
M-CSF neutralizing antibody to the culture (Fig. 3 D).
These results indicate that M-CSF stimulates the expression
of RANK on osteoclast precursor cells.
M-CSF and RANKL Cooperate in the Differentiation of
Osteoclasts. Next we analyzed how osteoclast precursor cells
differentiate into TRAP1 cells in the presence of M-CSF
and sRANKL rather than ST2 stromal cells. Fractionated
R3 cells were cultured for 72 h in IL-3 (100 U/ml) or M-CSF
(30 ng/ml). As shown in Fig. 4 A, M-CSF induced RANK
expression more efficiently than did IL-3. RANK1 or
RANK2 cells precultured with IL-3 or M-CSF for 72 h were
sorted and cultured in the presence of sRANKL and either
IL-3 or M-CSF. The percentage of TRAP1 cells is shown
in Fig. 4 B. Both IL-3– and M-CSF–precultured cells dif-
ferentiated into TRAP1 cells in the presence of sRANKL
and M-CSF. Moreover, RANK2 cells in each preculture
condition showed a higher percentage of TRAP1 cells than
RANK1 cells in the presence of sRANKL and M-CSF.
M-CSF–precultured cells showed a higher percentage of
TRAP1 cells than did IL-3–precultured cells.
To examine whether RANK1 cells differentiate to
TRAP1 cells in the presence of sRANKL alone, primary
R3 cells or R3 cells precultured with M-CSF were cultured
for 2, 4, or 6 d and analyzed for TRAP staining. RANK1
cells precultured for 24 h differentiated into TRAP1 cells,
and the percentage of TRAP1 cells decreased in the pres-
ence of sRANKL alone (Fig. 4 C). However, primary R3
cells (RANK1 or RANK2) or RANK2 cells precultured for
24 h did not differentiate into TRAP1 cells with sRANKL
alone. No TRAP1 cells were observed when cells were cul-
tured for 6 d with M-CSF alone (data not shown). These
data suggest that M-CSF affects not only the survival factor
but also the competence factor for osteoclast precursor cells
during their differentiation.
The Timing of RANKL Binding to Osteoclast Precursor Cells
Is Critical for Osteoclastogenesis. To clarify the synergistic ef-
fect of M-CSF and sRANKL, the relationship between the
onset of RANK expression and osteoclast differentiation
was examined. Fig. 5 shows the flow chart of cell sorting
and conditions of further cultivation. Sorted RANK1 or
RANK2 cells from the primary R3 fraction were cultured
for 2, 4, and 6 d with both sRANKL and M-CSF (Fig. 6, A
and B). On days 2 and 4, the percentage of TRAP1 cells was
higher in RANK2 cells (11.8 6 1.9% on day 2 and 97.5 6
1.4% on day 4) than in RANK1 cells (7.0 6 1.7% on day 2
and 42.5 6 6.1% on day 4). On day 6, however, the
percentage of TRAP1 cells was similar in RANK1 and
RANK2 cells. Interestingly, the percentage of TRAP1 cells
in R3 cells precultured for 24 h with M-CSF was similar be-
Figure 3. Expression of RANK on unfractionated BM cells or frac-
tionated cells. Expression of RANK mRNA was analyzed by RT-PCR.
(A) BM mononuclear cells were cultured with IL-3 (100 U/ml; left
panel) or M-CSF (30 ng/ml; right panel), and the expression of RANK
mRNA was examined before and after 24, 48, or 72 h of culture. (B)
Fractionated BM cells were cultured for 48 h with M-CSF (30 ng/ml),
and the expression of RANK was examined before and after 48 h of cul-
ture. (C) Expression of RANK protein on BM R3 or R5 cells was ana-
lyzed by FACS®. R3 (upper panels) or R5 (lower panels) cells were cul-
tured for 24 or 72 h with M-CSF (30 ng/ml), and the expression of
RANK was analyzed. Red line, anti-RANK; black line, rat IgG2a. (D)
R3 cells (c-Kit1Mac-1dullc-Fms1) were divided into RANK1 or RANK2
cells, and RANK2 R3 cells were cultured for 24 or 48 h in the presence of
M-CSF (30 ng/ml) with or without anti–mouse M-CSF neutralizing anti-
body (10 mg/ml). The expression of RANK was analyzed by RT-PCR.
were c-Kit2Mac-1highc-Fms1, and sorted RANK2 cells
were c-Kit2Mac-1dullc-Fms1 (data not shown). RANK ex-
pression in R3 cells was induced by stimulation of M-CSF;
however, R3 cells originally contained RANK1 cells.1747 Arai et al.
tween RANK1 and RANK2 cells (Fig. 6, C and D),
whereas in the case of R3 cells that were not precultured,
RANK1 cells did not efficiently differentiate into TRAP1
cells (Fig. 6, A and B). RANK2 cells showed a higher per-
centage of MNCs, which are fully matured osteoclasts, than
did RANK1 cells. These MNCs from RANK2 cells were
extremely large and contained a large number of nuclei.
Growth of RANK1 and RANK2 cells after 72 h of
preculture with M-CSF was less than that of primary or
24-h–precultured R3 cells (Fig. 6 E). Although the per-
centage of TRAP1 cells was higher in RANK2 cells than
RANK1 cells on day 4 (9.16 6 4.3% in RANK1 and 95.6 6
1.8% in RANK2 cells), the percentage was similar on day 6
(97.1 6 0.5% for RANK1 and 99.5 6 0.1% for RANK2
cells; Fig. 6 F). A delay in differentiation of TRAP1 cells
from RANK1 cells was observed. Also RANK2 cells
showed a higher percentage of TRAP1 MNCs than did
RANK1 cells, but this number was lower than that ob-
served in RANK2 cells precultured for 24 h. Moreover,
the size of MNCs was reduced and the number of nuclei
contained in MNCs was smaller in RANK2 cells precul-
tured for 72 h than in cells precultured for 24 h. 
Figure 4. Both RANKL and M-CSF regulate the differentiation of osteoclasts. (A) R3
cells were cultured with IL-3 (100 U/ml) or M-CSF (30 ng/ml) for 72 h. A fluorescence
histogram shows the RANK staining profile after 72-h cultivation with IL-3 (left panel) or
M-CSF (right panel). (B) RANK1 (black column) and RANK2 (white column) cells were
sorted from IL-3– or M-CSF–precultured R3 cells and were then cultured with sRANKL
(25 ng/ml) and IL-3 (100 U/ml) or M-CSF (100 ng/ml). The percentage of TRAP1 cells
was determined on day 4. (C) Percentages of TRAP1 cells differentiated from primary
RANK1 ( d), primary RANK2 ( s), and M-CSF 24-h–precultured RANK1 ( j) or
RANK2 (u) cells in the R3 fraction were determined after cultivation with sRANKL for
2, 4, or 6 d.
Figure 5. Flow chart of FACS® analysis and the points for further examination. Mouse BM c-Kit1 cells were divided into four fractions (R3, R4, R5,
and R6) as described in the Fig. 1 legend. The box enclosed with dashed lines indicates further analysis performed in Fig. 6. (a) R3 cells (c-Kit1Mac-
1dullc-Fms1) were subdivided into RANK1 or RANK2 cells, and each fraction was cultured in the presence of M-CSF and sRANKL. (b) R3 cells were
cultured for 24 or 72 h with M-CSF and were subdivided into RANK1 or RANK2 cells. 24- or 72-h–precultured RANK1 and RANK2 cells were
cultured with both M-CSF and sRANKL. Red line, cultivation with M-CSF and sRANKL; dark blue line, cultivation with M-CSF.1748 Commitment and Differentiation of Osteoclasts
Figure 6. Differentiation of
TRAP1 cells from RANK1 or
RANK2 cells. R3 cells were pre-
cultured with M-CSF (30 ng/ml)
for 24 or 72 h. These precultured
cells and primary R3 cells were
then divided into RANK1 or
RANK2 fractions. Primary and
cultured RANK1 or RANK2
cells were cultured with sRANKL
(25 ng/ml) and M-CSF (100 ng/
ml). (A and B) Primary R3 cells.
(C and D) 24-h M-CSF–precul-
tured cells. (E and F) M-CSF 72-
h–precultured cells. TRAP stain-
ing (A, C, and E) was performed
on day 2 (I and IV), day 4 (II and
V), or day 6 (III and VI), and the
percentage of TRAP1 cells or
TRAP1 MNCs (B, D, and F) was
scored at the same time. I, II, and
III were derived from RANK1
cells; IV, V, and VI were from
RANK2 cells. Scale bar, 100 mm.
Upper panels of B, D, and F repre-
sent percentages of TRAP1 cells
that include both mononuclear
cells and MNCs in the total cells in
the well. Lower panels of B, D,
and F represent percentages of
TRAP1 MNCs in total TRAP1
cells in the well. Percent of
TRAP1 cells or TRAP1 MNCs
derived from RANK1 ( j) or
RANK2 (u) cells is shown.
In all culture conditions, especially 24-h preculture with
M-CSF, the potential of cell growth of RANK2 cells was
greater than that of RANK1 cells. Also, RANK2 cells
formed a large number of MNCs, which contained high
numbers of nuclei because of the increment of cell density
induced by cell proliferation. In addition, when RANK1
and RANK2 cells were precultured with M-CSF for 24 h,
a higher number of TRAP1 cells was observed in the lat-1749 Arai et al.
ter, suggesting that RANK expression is necessary but not
sufficient for osteoclast differentiation and that the timing
of RANKL binding to RANK1 cells may be critical for
commitment of osteoclast cells.
The Osteoclast Precursor Cell Is Still Bipotential at a Late Stage
of Osteoclast Differentiation. Fractionated cells (R3 or R5) can
differentiate to lineages other than osteoclast (Tables II and
III); however, it is not clear whether a single osteoclast pre-
cursor cell is committed to differentiate into a TRAP1 cell or
whether it can differentiate into other lineages. To under-
stand the mechanism of osteoclast differentiation, R3 cells
were cultured in methylcellulose instead of liquid culture
(Fig. 7). 103 R3 cells were cultured with methylcellulose me-
dium containing M-CSF (100 ng/ml) in the presence or ab-
sence of sRANKL (25 ng/ml) for 7 d. In the absence of
both cytokines, colony formation was not detected, whereas
139 6 14.5 and 131 6 1.7 colonies were observed in M-CSF
alone and in M-CSF and sRANKL, respectively (Table IV).
Whereas colonies formed in the presence of M-CSF alone
were tightly compacted (Fig. 7 A), colonies observed in
M-CSF and RANKL were of mixed type (Fig. 7 B). Individ-
ual colonies in the presence of M-CSF and sRANKL con-
tained not only nonspecific esterase–positive macrophages but
also TRAP1 cells (Fig. 7, C–E). The percentage of TRAP1
cells in 20 colonies was 0 6 0% (M-CSF alone) and 43.8 6
30.4% (13.3–94.2%; M-CSF and sRANKL; Table IV). Any
homogeneous colonies consisting of all TRAP1 cells were
not observed. These data strongly suggest that single precur-
sor cells can differentiate into TRAP1 cells and macrophages
at a late stage of osteoclast differentiation.
Discussion
Here we identify early and late stages of osteoclast precur-
sor cells and describe the differentiation pathway of osteo-
clasts from hematopoietic precursor cells by coculture of
Figure 7. Colony formation from BM cells in the presence of
sRANKL and M-CSF. R3 cells were cultured in methylcellulose me-
dium with M-CSF (100 ng/ml) and sRANKL (25 ng/ml) for 7 d.
Shown are pure macrophage colonies in the presence of M-CSF (A),
colonies formed in the presence of sRANKL and M-CSF (B), and indi-
vidual cells in osteoclast-containing colonies stained for May-Grün-
wald-Giemsa (C), with nonspecific esterase (D), and for TRAP (E).
Scale bars, 10 mm (A and B) and 25 mm (C, D and E).1750 Commitment and Differentiation of Osteoclasts
c-Fms2, and their numbers decrease along with expression
of c-Fms (43). This observation is based on an assay of
TRAP1 cells on day 6 of culture, which is consistent with
our observation. We show that a later stage of osteoclast
precursor cells (c-Fms1RANK1) differentiates into TRAP1
osteoclasts in 2 d. It was reported that osteoclast precursor
cells were significantly higher in the c-Kitlow fraction, whereas
myeloid cells of other lineages were higher in the c-Kithigh
fraction (44). However, the c-Kithigh fraction contained a
similar number of osteoclast precursor cells (45).
We showed that c-Kit1Mac-1dullc-Fms2 cells can differ-
entiate not only into the myeloid lineage but also into
B2201 B cells in the presence of IL-7. On the other hand,
c-Kit1Mac-1dullc-Fms1 cells differentiate into osteoclasts at
a frequency of 1:5 on stromal cells. Stromal cells such as
ST2 express RANKL, and its expression can be upregu-
lated by the bone-resorbing factors 1,25-(OH)2D3, IL-11,
prostaglandin E2, and parathyroid hormone (46). How-
ever, the ST2 coculture system with 1,25-(OH)2D3 does
not maximally stimulate osteoclastogenesis, as ST2 also
produces the inhibitory molecule OPG/OCIF, which be-
longs to the TNFR family (47, 48).
Commitment of Osteoclasts. We investigated the com-
mitment process of c-Kit1Mac-1dullc-Fms1 cells to osteo-
clasts using M-CSF and sRANKL instead of stromal cells.
Our data suggest that M-CSF stimulates c-Kit1Mac-1dull
c-Fms1 cells to induce RANK mRNA and protein in 24 h
more efficiently than does IL-3. These cells can differenti-
ate into osteoclasts in the presence of both M-CSF and
sRANKL. With M-CSF only, they differentiate into mac-
rophages but not into osteoclasts. RANKL is a differentia-
tion factor for osteoclasts but not an exclusive osteoclast
commitment factor, as RANK is expressed not only in os-
teoclasts but in T cells and dendritic cells (24). Mice with a
disrupted RANKL (opgl) gene show severe osteopetrosis
and lack all lymph nodes (32), suggesting that RANKL–
RANK signaling plays several roles in organogenesis.
Preculture of c-Kit1Mac-1dullc-Fms1 cells with M-CSF
for 24 or 72 h results in different fates for osteoclast precur-
sors. RANK1 cells after 24-h preculture differentiate into
osteoclasts more efficiently than after 72-h preculture.
RANK1 cells may autonomously differentiate into the mac-
rophage lineage in the absence of sRANKL for 72 h. By con-
trast, in the presence of both sRANKL and M-CSF after
24-h preculture with M-CSF, RANK1 cells efficiently dif-
ferentiate into osteoclasts. RANK2 cells, after preculture
with M-CSF, may differentiate into RANK1 cells if they
are continuously exposed to M-CSF. Once the cells ex-
press RANK, existing RANKL binds to the receptors. This
is the most productive system for osteoclast differentiation,
which may take place in vivo on bone surfaces. Thus,
RANK2 cells differentiate into osteoclasts more efficiently
than RANK1 cells. Moreover, as their proliferative activity
is higher, multinuclear osteoclast formation from RANK2
cells is greater than that of RANK1 cells. This is dependent
upon the cell density (data not shown).
c-Kit1Mac-1dullc-Fms1 cells differentiate exclusively into
osteoclasts (z100%) in the presence of both M-CSF and
Table IV. Differentiation of Single Osteoclast Precursor Cell
No. of colonies TRAP1 cells
%
No factor 0 6 0N D
M-CSF alone 139 6 14.5 0 6 0
M-CSF 1 sRANKL 131 6 1.7 43.8 6 30.4
103 R3 cells were cultured in methylcellulose medium with M-CSF
(100 ng/ml) in the presence or absence of sRANKL (25 ng/ml). After 7 d
of cultivation, the number of colonies (containing .50 cells) was deter-
mined, and the percentage of TRAP1 cells in each colony was calcu-
lated. The data shown represents the mean number of colonies 6 SD.
those cells with the ST2 stromal cell line and 1,25-(OD)2D3.
We also analyze the osteoclast commitment process by sub-
stituting M-CSF and sRANKL for the stromal cells.
Identification of Osteoclast Precursors. Hematopoietic pre-
cursor cells exist in the c-Kit1 fraction (34, 35). This fraction
was clearly subdivided by the expression of c-Fms and
Mac-1. Mac-11 cells contain mainly mature granulocytes and
macrophages, whereas Mac-1dull cells are multipotential pro-
genitor cells (36, 37). We demonstrate that c-Kit1Mac-
1dullc-Fms1 cells in murine BM are early stage precursors of
osteoclasts using a limiting dilution method. These cells are
shown to be derived from c-Kit1Mac-1dullc-Fms2 cells. We
show directly that c-Fms2 cells differentiate into c-Fms1
cells after 2 d in culture with SCF. It has been previously re-
ported that c-Fms is a key determinant in the differentiation
of monocyte–macrophage lineage cells (38). c-Fms expres-
sion is regulated by a tissue-specific promoter. Although the
precise mechanism of c-Fms expression is not known, tran-
scription factors c-ets-1, c-ets-2, and PU.1 mediate induc-
tion of c-Fms (39–41). Thus, it is reasonable that c-Kit1
Mac-1dullc-Fms1 cells differentiate into TRAP1 osteoclasts
after 4 d, whereas c-Kit1Mac-1dullc-Fms2 cells require .7 d.
In addition, c-Kit1Mac-1dullc-Fms1 cells express the RANK
mRNA and protein in 24 h in the presence of M-CSF.
Lacey et al. (21) demonstrated that osteoclast precursor cells
were identified by sRANKL–FITC. They sorted sRANKL–
FITC1 cells after cultivation of mouse BM cells in the pres-
ence of M-CSF and sRANKL for 1 d, and these precur-
sor cells were therefore regarded as RANK1 cells. These
sRANKL–FITC1 cells formed a larger number of multinu-
cleated TRAP1 cells than sRANKL–FITC2 cells. In con-
trast to this finding, we found that a large number of multi-
nucleated TRAP1 cells were derived from RANK2 rather
than RANK1 cells, regardless of precultivation with M-CSF
(Fig. 6). By cultivation with M-CSF and sRANKL for 1 d
before cell sorting, it is speculated that sRANKL–FITC1
cells have already been committed to osteoclast lineage. We
show a sequential change of phenotype in the differentiation
pathway of osteoclasts (Fig. 8 A).
Although an mAb against c-Fms suppresses osteoclasto-
genesis (42), most osteoclast precursors in BM are c-Kit11751 Arai et al.
sRANKL. As even RANK1 cells can differentiate into mac-
rophages, we conclude that the stage of commitment of os-
teoclasts is late in the differentiation process. A clonal assay
using colony formation in semisolid methylcellulose me-
dium provided us with precise identification of constituent
cells and revealed no pure osteoclast colonies in the pres-
ence of both M-CSF and sRANKL. A single colony con-
tained 13.3–94.2% TRAP1 osteoclasts. This observation
suggests the very low incidence of osteoclast colony form-
ing cells, which are exclusively committed to osteoclasts.
The growth of osteoclasts in methylcellulose is poorer than
that observed in a liquid culture system, which enables os-
teoclasts to attach to the culture dish. Cell anchoring or po-
larity is critical for osteoclast differentiation. A study of cell
adhesion molecules expressed by osteoclasts is underway.
Function of M-CSF in Osteoclastogenesis. Our findings sug-
gest that M-CSF plays three roles in osteoclastogenesis: (a)
it induces RANK, (b) it is a competence factor for differ-
entiation, and (c) it stimulates cell survival and proliferation
(Fig. 8 B). Although upregulation of RANK by M-CSF is
higher than that by IL-3 (Figs. 3 A and 4 A) and GM-CSF
(data not shown), RANK induction is not M-CSF specific.
Even though expression of RANK on RANK2 cells was
upregulated in the presence of M-CSF and its expression
was significantly inhibited by addition of neutralizing
M-CSF antibody (Fig. 3 D), further analysis in association
with the signaling pathway would be necessary to elucidate
the mechanism of c-Fms–RANK interaction.
As shown in Fig. 4 C, TRAP1 cells differentiated from
M-CSF–precultured RANK1 cells but not from primary
RANK1 cells in the presence of sRANKL alone, suggest-
ing that unknown events induced by M-CSF are competent
for differentiation to osteoclasts. Without M-CSF, RANKL–
RANK could not induce osteoclasts even in the presence
Figure 8. Model of osteoclast differentiation derived from hematopoietic stem cells. (A) Sequential phenotypic progression of osteoclasts and relevant
factors. (B) Determination of osteoclastic differentiation in the presence of M-CSF and RANKL.1752 Commitment and Differentiation of Osteoclasts
of IL-3. It will be interesting to define the molecular event
induced by M-CSF in precursors. As RANK belongs to
the TNFR family and does not stimulate cell proliferation,
M-CSF–precultured RANK1 cells could not survive and
proliferate without the continuous presence of M-CSF. It
has been shown that RANKL stimulates mature osteoclasts
to activate bone resorption (49). In the absence of RANKL,
precursor cells autonomously differentiate into macrophages
in the presence of M-CSF, a situation regarded as the de-
fault pathway of macrophagic differentiation. The determi-
nation of osteoclastic differentiation is achieved to avoid
the default pathway of macrophagic differentiation from the
signal of the RANK–RANKL system (Fig. 8 B).
Spontaneous recovery of adult op/op mice suggests the
presence of unknown molecules (50, 51). The osteoclast
defect in M-CSF mutant osteopetrotic mice can be rescued
by overexpression of the antiapoptotic protein Bcl-2 in the
monocyte lineage (14). Although M-CSF is an indispens-
able factor for osteoclastogenesis, other molecules may in-
duce RANK less efficiently than M-CSF. It is noteworthy
that the intracellular domain of RANK directly binds
TRAF2, TRAF5, and TRAF6 (26, 28), and TRAF6 defi-
ciency results in osteopetrosis (29).
In conclusion, we have identified osteoclast precursor cells
and clarified the function of M-CSF and RANKL. The co-
operation of these two factors is critical for osteoclast differ-
entiation. Osteoclastogenesis is thus a unique model system
in the lineage determination of blood cell differentiation.
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